{
    "clinical_study": {
        "@rank": "63962", 
        "brief_summary": {
            "textblock": "This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating\n      alcoholism.  Individuals will be inpatients for a 2 week period and provide assessments of\n      their alcohol withdrawal symptoms, craving, and mood.  Following hospital discharge,\n      individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or\n      a placebo.  This part of the study will last 12 weeks, with regular measurements of drinking\n      level, craving and mood.  Assessments will be conducted 6 and 12 months after the beginning\n      of the study."
        }, 
        "brief_title": "Naltrexone Treatment for Alcoholism", 
        "completion_date": "March 2003", 
        "condition": "Alcoholism", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets criteria for alcohol dependence.\n\n          -  Committed to alcohol abstinence as a treatment goal.\n\n          -  Individuals will be required to identify two family members or close friends who are\n             knowledgeable about their location, drinking behavior, and psychosocial status.\n\n        Exclusion Criteria:\n\n          -  Meets criteria for any other psychoactive substance use disorder (excluding nicotine\n             and caffeine).\n\n          -  Meets criteria for a major psychiatric disorder and are in need of or currently\n             undergoing pharmacotherapy.\n\n          -  Females who are pregnant, lactating, or not using a reliable method of contraception.\n\n          -  Currently experiencing a serious medical condition that would place them at risk or\n             interfere with study participation.\n\n          -  Experiencing acute hepatitis or liver failure or whose liver function test is more\n             than 3 times normal.\n\n          -  Have a history of severe allergies, multiple adverse drug reactions or known allergy\n             to naltrexone.\n\n          -  Vocabulary below the 5th grade reading level.\n\n          -  Abnormal MRI scan.\n\n          -  HIV infection due to the neurological sequelae.\n\n          -  Significant central nervous system diseases.\n\n          -  Seizure disorder or history of closed head trauma.\n\n          -  Neuroendocrine disorders.\n\n          -  Treatment with opiates within the last six months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": "192", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000438", 
            "org_study_id": "NIAAAMCC11855", 
            "secondary_id": "R01AA011855"
        }, 
        "intervention": {
            "intervention_name": "naltrexone (Revia)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Naltrexone"
        }, 
        "lastchanged_date": "May 13, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Naltrexone Treatment for Alcoholism: Predicting Outcome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000438"
        }, 
        "responsible_party": {
            "name_title": "Mary E. McCaul, Ph.D., Professor", 
            "organization": "Johns Hopkins University"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2010"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hospital": "39.29 -76.612"
    }
}